FDA Proposes Permanent Exclusion of GLP-1s From 503B Bulks List
The FDA has formally proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period closed July 30, 2026, with no final decision timeline announced.
